Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s...
Olympus Corp. of the Americas is proud to announce the new iTind™ Center of Excellence (COE) Program, which is designed to enhance care, experience...
Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, announced a strategic collaboration with Maxymune Therapeutics, a ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Sapio Sciences, the science-awareTM lab informatics platform, announced a strategic partnership with Ultima Genomics. The collaboration will make m...
Booking Health, a global medical travel platform, announced the expansion of patient access to dendritic cell immunotherapy for recurrent glioblastoma, f...
-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...
Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, published research in mB...
23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the official launch of an open-source data platform for the...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that first-line treatment with RYBREVANT® (amivantamab-vmj...
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...
Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has approved HERNEXEOS® (zongertinib tablets)...
© 2025 Biopharma Boardroom. All Rights Reserved.
